What drove the RDC.DE stock drop today?

RDC.DE stock fell **-21.01%** after FY25 results showed a slowdown in OTC sales despite revenue growth. Heavy selling on XETRA and a spike to **896,005** shares amplified the move.

What is Meyka AI's view on RDC.DE stock?

Meyka AI rates RDC.DE **71.61 (B+)** with a BUY suggestion. The model highlights revenue growth but flags margin and free cash flow risks; forecasts are projections, not guarantees.

What price targets should investors watch for RDC.DE stock?

Short-term model guidance points to **€36.44** (quarterly) and **€70.25** (monthly). Meyka AI's 12-month projection is **€94.92**, implying large upside if profitability recovers.

How should traders manage risk in RDC.DE stock?

Use tight risk controls: consider a stop-loss below the year low **€45.92**, watch volume when re-entering, and avoid adding size until free cash flow and EPS show consistent improvement.

DE Stocks

RDC.DE Redcare Pharmacy (XETRA) market closed: shares -21.01% on earnings, outlook

ByDanny Kontos March 5, 2026March 5, 2026

RDC.DE stock plunged -21.01% to €47.00 at market close after Redcare Pharmacy N.V. reported FY25 results and commentary that left traders uncertain. The move came on a volume spike of 896,005 shares versus an average of 91,665, signalling a fast reposition by investors. Redcare showed revenue growth but mixed margins and a slowdown in OTC sales that weighed on the share price. We summarise the key earnings figures, valuation metrics, technical levels and what the Meyka AI grade and forecasts imply for traders on XETRA in Germany.